{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:40:12Z","timestamp":1768542012706,"version":"3.49.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T00:00:00Z","timestamp":1182816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS\u2010247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi\u2010institutional setting in patients previously treated with 1 prior chemotherapy regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Forty\u2010five patients with advanced urothelial carcinoma were treated with BMS\u2010247550 40 mg\/m<jats:sup>2<\/jats:sup> over 3 hours intravenously on Day 1 of a 21\u2010day cycle and continued therapy until progression or unacceptable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Five patients obtained an objective partial response (PR) among the 42 eligible patients for an overall response rate of 11.9% (90% confidence interval [5.3%, 26.5%]). Median overall survival of the group was 8 months. Toxicity was moderate with granulocytopenia, fatigue, and sensory neuropathy being the most common side effects noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>BMS\u2010247550 (ixabepilone) has very modest activity as a second\u2010line therapy for advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and sensory neuropathy was common. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22839","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T12:17:14Z","timestamp":1182860234000},"page":"759-763","source":"Crossref","is-referenced-by-count":71,"title":["Phase 2 trial of epothilone B analog BMS\u2010247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)"],"prefix":"10.1002","volume":"110","author":[{"given":"Robert","family":"Dreicer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Manola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,26]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2264"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6699"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1853"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.152"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00075-7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.589"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.1997.15.6.2449","article-title":"Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional\u2010cell carcinoma","volume":"15","author":"McCaffrey JA","year":"1997","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200101000-00017"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.001"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.4.2534"},{"key":"e_1_2_5_13_2","first-page":"1429","article-title":"BMS\u2010247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee F","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0919-03"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.063"},{"key":"e_1_2_5_16_2","first-page":"2035","article-title":"Validation of the pharmacodynamics of BMS\u2010247550, an analog of epothilone B, during a phase I clinical study","volume":"8","author":"McDaid H","year":"2002","journal-title":"Clin Can Res."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02292-8"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603118"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4448"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22839","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:16:27Z","timestamp":1760271387000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22839"}},"subtitle":["A trial of the eastern cooperative oncology group"],"short-title":[],"issued":{"date-parts":[[2007,6,26]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,15]]}},"alternative-id":["10.1002\/cncr.22839"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22839","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,26]]}}}